{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:49Z","timestamp":1790286949113,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy is a significant development in cancer therapy that is used to treat B-cell malignancies including B cell lymphoblastic leukemias, relapsed and refractory lymphomas, and multiple myeloma. CAR-T requires T-cell collection from the patient, which is genetically engineered to express a synthetic receptor that will bind to an antigen of a specific tumor. The CAR-T cells are then infused back into the patient, which function to attack the resistant cancer cells. Reported side effects of CAR-T include cytokine-release syndrome (CRS), macrophage activation syndrome (MAS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Sometimes, patients can experience rare side effects which are not reported as often due to the rarity. We present a series of three patients with relapsed\/refractory diffuse large B-cell lymphoma, who each received CAR-T therapy with Axicabtagene ciloleucel. Each patient developed unique and unprecedented adverse effects in the time following infusion of CAR-T. This includes manifestations of autoimmune demyelination and myelopathy, bullous dermatologic reactions on the lower extremities, and bilateral enlarged parotid glands as a result of CAR-T.<\/jats:p>","DOI":"10.3389\/fonc.2025.1644818","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:11:09Z","timestamp":1762837869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Rare adverse events following CAR-T therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Ziniya","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Kunwor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904497","article-title":"CAR T-cell therapy predictive response markers in diffuse large B-cell lymphoma and therapeutic options after CART19 failure","volume":"13","author":"Caballero","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: A translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: A versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","article-title":"Chimeric antigen receptor T-cell therapy","volume-title":"StatPearls","author":"Zhang","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.031","article-title":"Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score","volume":"26","author":"Herr","year":"2020","journal-title":"Biol Blood marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.8.9","article-title":"Axicabtagene ciloleucel: the first FDA-approved CAR T-cell therapy for relapsed\/refractory large B-cell lymphoma","volume":"10","author":"King","year":"2019","journal-title":"J advanced practitioner Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.286","article-title":"Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma","volume":"3","author":"Sheikh","year":"2021","journal-title":"EJHaem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020382","article-title":"Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1182\/blood-2024-210573","article-title":"Managing CAR T-cell toxicity: impact of steroid prophylaxis on toxicity and outcomes","volume":"144","author":"Upadhyay","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.36000\/HBT.OH.2024.19.138","article-title":"Rare adverse events of CAR T-cell therapy","volume":"19","author":"M\u00fcller","year":"2024","journal-title":"healthbook TIMES Onco Hema"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.24035","article-title":"Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: A case series","volume":"64","author":"Kawase","year":"2024","journal-title":"J Clin Exp hematopathology: JCEH"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0636","article-title":"Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma","volume":"156","author":"Hu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.07.042","article-title":"Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction","volume":"40","author":"Miranda","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14687","article-title":"Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma","volume":"51","author":"Bhullar","year":"2024","journal-title":"J Cutan Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1644818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:11:10Z","timestamp":1762837870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1644818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1644818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1644818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1644818"}}